Breakthrough Blood Test May Revolutionise Prostate Cancer Screening in UK

On 13 January 2026, researchers at the University of Cambridge announced encouraging findings from a novel blood test designed to detect prostate cancer. The study, published in the UK media, noted that current Prostate‑Specific Antigen (PSA) tests lack sufficient accuracy for widescale screening, especially in asymptomatic men. The new assay, still in early clinical stages, shows potential to identify early‑stage tumours with higher specificity, reducing false positives. While the trial involved several hundred volunteers across Cambridge and London clinics, it marks a significant advance for UK public health officials who are scrutinising feasible screening strategies. The next phase aims to validate the test across a national cohort before potential NHS adoption.